Benzinga | Jun 8, 2021 07:05AM EDT

Rockwell Medical And Drogsan Pharmaceuticals Enter Exclusive License Agreement For Rights To Commercialize Triferic In Turkey; Financial Details Not Disclosed

Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, and Drogsan Pharmaceuticals, a leading pharmaceutical company in Turkey with an established presence in the nephrology space having launched the first locally manufactured biosimilar in 2014 and building it to be the leader in the Epoetin Alfa market in Turkey, today announced that the Companies entered into an exclusive license agreement for the rights to commercialize Triferic AVNU (ferric pyrophosphate citrate injection) in Turkey.